The landscape of oncological screening has advanced rapidly as the US Food and Drug Administration granted its highly coveted FDA breakthrough device designation to Natera’s investigational multi-cancer early detection (MCED) blood test. This cutting-edge liquid biopsy technology utilizes advanced genetic mapping to detect precise, cancer-specific DNA methylation signatures circulating in the bloodstream. The regulatory clearance effectively fast-tracks the test’s clinical validation and development timeline, bringing non-invasive genomic monitoring one step closer to becoming a standard component of preventative healthcare.
About the Author
